Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


11.06.2018

5 Aliment Pharmacol Ther
1 Am J Gastroenterol
4 Dig Dis Sci
1 Eur J Gastroenterol Hepatol
5 Inflamm Bowel Dis
2 J Crohns Colitis
1 J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. ALUKAIDEY S, Heerasing N
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice.
    Aliment Pharmacol Ther. 2018;47:1539-1540.
    PubMed     Text format    

  2. UNGARO R, Colombel JF
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1540.
    PubMed     Text format    

  3. PARK KT, Sceats L, Dehghan M, Trickey AW, et al
    Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 7. doi: 10.1111/apt.14842.
    PubMed     Text format     Abstract available

  4. GONCALVES J, Santos M, Acurcio R, Iria I, et al
    Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14808.
    PubMed     Text format     Abstract available

  5. BAE JM, Lee HH, Lee BI, Lee KM, et al
    Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14822.
    PubMed     Text format     Abstract available


    Am J Gastroenterol

  6. MAO R, Chen MH
    Networked Clinical Study Collaboration on Inflammatory Bowel Disease in China.
    Am J Gastroenterol. 2018 Jun 7. pii: 10.1038/s41395-018-0148.
    PubMed     Text format    


    Dig Dis Sci

  7. KOK B, Lester ELW, Lee WM, Hanje AJ, et al
    Acute Liver Failure from Tumor Necrosis Factor-alpha Antagonists: Report of Four Cases and Literature Review.
    Dig Dis Sci. 2018;63:1654-1666.
    PubMed     Text format     Abstract available

  8. ELURI S, Cross RK, Martin C, Weinfurt KP, et al
    Inflammatory Bowel Diseases Can Adversely Impact Domains of Sexual Function Such as Satisfaction with Sex Life.
    Dig Dis Sci. 2018;63:1572-1582.
    PubMed     Text format     Abstract available

  9. ARORA U, Kedia S, Garg P, Bopanna S, et al
    Colonic Crohn's Disease Is Associated with Less Aggressive Disease Course Than Ileal or Ileocolonic Disease.
    Dig Dis Sci. 2018;63:1592-1599.
    PubMed     Text format     Abstract available

  10. WANG P, Hu J, Ghadermarzi S, Raza A, et al
    Smoking and Inflammatory Bowel Disease: A Comparison of China, India, and the USA.
    Dig Dis Sci. 2018 Jun 4. pii: 10.1007/s10620-018-5142.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  11. O'CONNELL J, Rowan C, Stack R, Harkin G, et al
    Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2018 Jun 6. doi: 10.1097/MEG.0000000000001177.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  12. ANDERSON A, Click B, Ramos-Rivers C, Koutroubakis IE, et al
    The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2018 May 31. pii: 5025926. doi: 10.1093.
    PubMed     Text format     Abstract available

  13. CHANDRADEVAN R, Hofmekler T, Mondal K, Harun N, et al
    Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles.
    Inflamm Bowel Dis. 2018 May 30. pii: 5025792. doi: 10.1093.
    PubMed     Text format     Abstract available

  14. KELSO M, Feagins LA
    Can Smartphones Help Deliver Smarter Care for Patients With Inflammatory Bowel Disease?
    Inflamm Bowel Dis. 2018 Jun 4. pii: 5032595. doi: 10.1093.
    PubMed     Text format     Abstract available

  15. ATREJA A
    Smarter Care for Patients With Inflammatory Bowel Disease: A Necessity for IBD Home, Value-Based Health Care and Treat-to-Target Strategies.
    Inflamm Bowel Dis. 2018 Jun 4. pii: 5032596. doi: 10.1093.
    PubMed     Text format    

  16. BLAZQUEZ ML, Hernani MT, Calatayud GA, Gonzalez-Pinto LC, et al
    Transition Care Program of Adolescents With Inflammatory Bowel Disease: Perceptions From A Survey for Patients.
    Inflamm Bowel Dis. 2018 Jun 5. pii: 5033090. doi: 10.1093.
    PubMed     Text format    


    J Crohns Colitis

  17. GUIDI L, Pugliese D, Panici Tonucci T, Berrino A, et al
    Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study.
    J Crohns Colitis. 2018 May 31. pii: 5026188. doi: 10.1093.
    PubMed     Text format     Abstract available

  18. PAUL S, Williet N, Di Bernado T, Berger AE, et al
    Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    J Crohns Colitis. 2018 May 31. pii: 5026191. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Gastroenterol

  19. SCHREIBER S, Dignass A, Peyrin-Biroulet L, Hather G, et al
    Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
    J Gastroenterol. 2018 Jun 4. pii: 10.1007/s00535-018-1480.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: